Tumor-associated factors are enriched in lymphatic exudate compared to plasma in metastatic melanoma patients

Maria A.S. Broggi, Lea Maillat, Cristina C. Clement, Natacha Bordry, Patricia Corthésy, Aymeric Auger, Maurice Matter, Romain Hamelin, Lambert Potin, Davide Demurtas, Emanuela Romano, Alexandre Harari, Daniel E. Speiser, Laura Santambrogio, Melody A. Swartz

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Liquid biopsies allow monitoring of cancer progression and detection of relapse, but reliable biomarkers in melanoma are lacking. Because secreted factors preferentially drain to lymphatic vessels before dilution in the blood, we hypothesized that lymph should be vastly enriched in cancer biomarkers. We characterized postoperative lymphatic exudate and plasma of metastatic melanoma patients after lymphadenectomy and found a dramatic enrichment in lymphatic exudate of tumor-derived factors and especially extracellular vesicles containing melanoma-associated proteins and miRNAs, with unique protein signatures reflecting early versus advanced metastatic spread. Furthermore, lymphatic exudate was enriched in memory T cells, including tumor-reactive CD137 + and stem cell–like types. In mice, lymph vessels were the major route of extracellular vesicle transport from tumors to the systemic circulation. We suggest that lymphatic exudate provides a rich source of tumor-derived factors for enabling the discovery of novel biomarkers that may reflect disease stage and therapeutic response.

Original languageEnglish (US)
Pages (from-to)1091-1107
Number of pages17
JournalJournal of Experimental Medicine
Volume216
Issue number5
DOIs
StatePublished - May 1 2019

Fingerprint

Exudates and Transudates
Melanoma
Lymph
Neoplasms
Biomarkers
Lymphatic Vessels
Tumor Biomarkers
Lymph Node Excision
MicroRNAs
Causality
Proteins
T-Lymphocytes
Biopsy
Recurrence
Extracellular Vesicles

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

Broggi, M. A. S., Maillat, L., Clement, C. C., Bordry, N., Corthésy, P., Auger, A., ... Swartz, M. A. (2019). Tumor-associated factors are enriched in lymphatic exudate compared to plasma in metastatic melanoma patients. Journal of Experimental Medicine, 216(5), 1091-1107. https://doi.org/10.1084/jem.20181618

Tumor-associated factors are enriched in lymphatic exudate compared to plasma in metastatic melanoma patients. / Broggi, Maria A.S.; Maillat, Lea; Clement, Cristina C.; Bordry, Natacha; Corthésy, Patricia; Auger, Aymeric; Matter, Maurice; Hamelin, Romain; Potin, Lambert; Demurtas, Davide; Romano, Emanuela; Harari, Alexandre; Speiser, Daniel E.; Santambrogio, Laura; Swartz, Melody A.

In: Journal of Experimental Medicine, Vol. 216, No. 5, 01.05.2019, p. 1091-1107.

Research output: Contribution to journalArticle

Broggi, MAS, Maillat, L, Clement, CC, Bordry, N, Corthésy, P, Auger, A, Matter, M, Hamelin, R, Potin, L, Demurtas, D, Romano, E, Harari, A, Speiser, DE, Santambrogio, L & Swartz, MA 2019, 'Tumor-associated factors are enriched in lymphatic exudate compared to plasma in metastatic melanoma patients', Journal of Experimental Medicine, vol. 216, no. 5, pp. 1091-1107. https://doi.org/10.1084/jem.20181618
Broggi, Maria A.S. ; Maillat, Lea ; Clement, Cristina C. ; Bordry, Natacha ; Corthésy, Patricia ; Auger, Aymeric ; Matter, Maurice ; Hamelin, Romain ; Potin, Lambert ; Demurtas, Davide ; Romano, Emanuela ; Harari, Alexandre ; Speiser, Daniel E. ; Santambrogio, Laura ; Swartz, Melody A. / Tumor-associated factors are enriched in lymphatic exudate compared to plasma in metastatic melanoma patients. In: Journal of Experimental Medicine. 2019 ; Vol. 216, No. 5. pp. 1091-1107.
@article{ce8bb7c09e3342d49efc62e37ff238cf,
title = "Tumor-associated factors are enriched in lymphatic exudate compared to plasma in metastatic melanoma patients",
abstract = "Liquid biopsies allow monitoring of cancer progression and detection of relapse, but reliable biomarkers in melanoma are lacking. Because secreted factors preferentially drain to lymphatic vessels before dilution in the blood, we hypothesized that lymph should be vastly enriched in cancer biomarkers. We characterized postoperative lymphatic exudate and plasma of metastatic melanoma patients after lymphadenectomy and found a dramatic enrichment in lymphatic exudate of tumor-derived factors and especially extracellular vesicles containing melanoma-associated proteins and miRNAs, with unique protein signatures reflecting early versus advanced metastatic spread. Furthermore, lymphatic exudate was enriched in memory T cells, including tumor-reactive CD137 + and stem cell–like types. In mice, lymph vessels were the major route of extracellular vesicle transport from tumors to the systemic circulation. We suggest that lymphatic exudate provides a rich source of tumor-derived factors for enabling the discovery of novel biomarkers that may reflect disease stage and therapeutic response.",
author = "Broggi, {Maria A.S.} and Lea Maillat and Clement, {Cristina C.} and Natacha Bordry and Patricia Corth{\'e}sy and Aymeric Auger and Maurice Matter and Romain Hamelin and Lambert Potin and Davide Demurtas and Emanuela Romano and Alexandre Harari and Speiser, {Daniel E.} and Laura Santambrogio and Swartz, {Melody A.}",
year = "2019",
month = "5",
day = "1",
doi = "10.1084/jem.20181618",
language = "English (US)",
volume = "216",
pages = "1091--1107",
journal = "Journal of Experimental Medicine",
issn = "0022-1007",
publisher = "Rockefeller University Press",
number = "5",

}

TY - JOUR

T1 - Tumor-associated factors are enriched in lymphatic exudate compared to plasma in metastatic melanoma patients

AU - Broggi, Maria A.S.

AU - Maillat, Lea

AU - Clement, Cristina C.

AU - Bordry, Natacha

AU - Corthésy, Patricia

AU - Auger, Aymeric

AU - Matter, Maurice

AU - Hamelin, Romain

AU - Potin, Lambert

AU - Demurtas, Davide

AU - Romano, Emanuela

AU - Harari, Alexandre

AU - Speiser, Daniel E.

AU - Santambrogio, Laura

AU - Swartz, Melody A.

PY - 2019/5/1

Y1 - 2019/5/1

N2 - Liquid biopsies allow monitoring of cancer progression and detection of relapse, but reliable biomarkers in melanoma are lacking. Because secreted factors preferentially drain to lymphatic vessels before dilution in the blood, we hypothesized that lymph should be vastly enriched in cancer biomarkers. We characterized postoperative lymphatic exudate and plasma of metastatic melanoma patients after lymphadenectomy and found a dramatic enrichment in lymphatic exudate of tumor-derived factors and especially extracellular vesicles containing melanoma-associated proteins and miRNAs, with unique protein signatures reflecting early versus advanced metastatic spread. Furthermore, lymphatic exudate was enriched in memory T cells, including tumor-reactive CD137 + and stem cell–like types. In mice, lymph vessels were the major route of extracellular vesicle transport from tumors to the systemic circulation. We suggest that lymphatic exudate provides a rich source of tumor-derived factors for enabling the discovery of novel biomarkers that may reflect disease stage and therapeutic response.

AB - Liquid biopsies allow monitoring of cancer progression and detection of relapse, but reliable biomarkers in melanoma are lacking. Because secreted factors preferentially drain to lymphatic vessels before dilution in the blood, we hypothesized that lymph should be vastly enriched in cancer biomarkers. We characterized postoperative lymphatic exudate and plasma of metastatic melanoma patients after lymphadenectomy and found a dramatic enrichment in lymphatic exudate of tumor-derived factors and especially extracellular vesicles containing melanoma-associated proteins and miRNAs, with unique protein signatures reflecting early versus advanced metastatic spread. Furthermore, lymphatic exudate was enriched in memory T cells, including tumor-reactive CD137 + and stem cell–like types. In mice, lymph vessels were the major route of extracellular vesicle transport from tumors to the systemic circulation. We suggest that lymphatic exudate provides a rich source of tumor-derived factors for enabling the discovery of novel biomarkers that may reflect disease stage and therapeutic response.

UR - http://www.scopus.com/inward/record.url?scp=85065539603&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85065539603&partnerID=8YFLogxK

U2 - 10.1084/jem.20181618

DO - 10.1084/jem.20181618

M3 - Article

VL - 216

SP - 1091

EP - 1107

JO - Journal of Experimental Medicine

JF - Journal of Experimental Medicine

SN - 0022-1007

IS - 5

ER -